Ergoteles LLC Tcr2 Therapeutics Inc. Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$1.0 - $1.62 $12,129 - $19,648	12,129 Added 26.86%	57,279 $85,000
Q4 2022 Feb 14, 2023	SELL	$0.83 - $1.44 $54,380 - $94,347	-65,519 Reduced 59.2%	45,150 $45,000
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $68,319 - $137,741	-36,731 Reduced 24.92%	110,669 $199,000
Q2 2022 Aug 12, 2022	BUY	$2.11 - $2.94 $311,014 - $433,356	147,400 New	147,400 $427,000
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $59,998 - $109,254	-13,100 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $110,564 - $240,385	13,100 New	13,100 $111,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.